Regeneron Ventures
VC Fund
Regeneron Ventures is a health care venture capital fund.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Regeneron Ventures invests in
Stages Regeneron Ventures invests in
Countries Regeneron Ventures invests in
Round sizes
Round size
- Series A
- $48M–$135M
- Series B
- $40M–$175M
Investment Focus
Industry
- Biotechnology 13 (76%)
- Health Care 8 (47%)
- Life Science 7 (41%)
- Therapeutics 7 (41%)
- Biopharma 5 (29%)
Stage
- Series B 8 (47%)
- Series A 6 (35%)
- Series C 1 (6%)
- Funding Round 1 (6%)
Country
- United States 14 (82%)
- Belgium 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Infinimmune operates as a biotechnology company. Infinimmune reinvents antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. | $75M / Series A / Aug 11, 2026 | ||
| City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. | $99.5M / Series B / Jun 08, 2026 | ||
| Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | ||
| Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Its mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.” | $100M / Series B / Apr 13, 2026 | ||
| Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M / Series B / Mar 05, 2026 | ||
| Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems. | $55M / Series A / Jan 20, 2026 | ||
| Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M / Series B / Dec 18, 2025 | ||
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M / Series B / Dec 03, 2025 | |
| The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant, a multi-modal transformer model that predicts clinical outcomes from the earliest stages of discovery, and NeuralPLexer, the best-in-class predictor of protein and protein-ligand structures.The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multi-parameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated experimental execution, Iambic completes design-make-test cycles on a weekly cadence. | $127.8M / Nov 10, 2025 | ||
| Zag Bio™ has discovered a novel approach to create thymus-targeted medicines to treat and prevent autoimmune diseases by restoring central immune tolerance. Zag Bio designs bifunctional antibodies that deliver self-antigens to antigen-presenting cells in the thymus to harness the body’s natural process for training immune cells to recognize andtolerate self, halting or preventing autoimmune attacks on the body’s own tissues. Zag Bio’s pipeline includes ZAG-101, its lead program for Type 1 diabetes, as well as discovery programs for thymus-targeted therapies to address other autoimmune diseases and help patients and their caregivers. Located in Cambridge, Massachusetts, Zag Bio’s team includes experienced experts in thymus biology, autoimmune diseases and innovative drug development.Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases. | $80M / Series A / Oct 28, 2025 | ||
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Regeneron Ventures invest in?
Regeneron Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series B and Series A stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Regeneron Ventures's check size?
Regeneron Ventures typically joins rounds of $48M–$135M at Series A and $40M–$175M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Regeneron Ventures participates in.
When did Regeneron Ventures last invest?
The most recent investment recorded for Regeneron Ventures closed in Aug 2026. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
